Podcasts about gingko bioworks

We treat water with oil - true story! Coagulants and Flocculants used in wastewater treatment are oil-based and often feature Polyacrylamide (or PAM). But there's no other way around, right? Well, there's one, and it looks (very!) promising. Wanna find out? Listen to this! More #water insights? Connect with me on Linkedin: https://www.linkedin.com/in/antoinewalter1/ #️⃣ All the Links Mentioned in this Video #️⃣ My conversation with Gingko Bioworks: https://smartlink.ausha.co/dont-waste-water/s10e9-coding-the-future-ginkgo-bioworks-synthesis-of-biology-and-technology My Growth Story with MembrIon: https://www.youtube.com/watch?v=jPlXltrIvWU Talk with Amielle on LinkedIn: https://www.linkedin.com/in/amiellelake/ ... or per email: amielle@carbonet.com

In which Dr. Jimmy Sastra, co-founder and CEO of Monomer Bio, discusses how automation can drive greater scalability, standardization, and data accessibility in complex cell culture workflows. We also chat about the importance of building killer apps and not just platforms, the fickleness of growing stem cells, the software layer behind Waymos, and Jimmy's philosophy on building a mission-driven team. Hosted by Emma Chen. Timestamps: (00:00) Intro (02:45) Monomer Bio (06:00) The challenge and opportunity of complex cell workflows (10:47) Timeline of collaborations (11:57) Onsite automation v.s. cloud labs (15:58) From initial interest in biology to PhD (24:08) Building killer apps and not just platforms (26:28) Partnership with Gingko Bioworks and Lilly Life Sciences Studio (28:25) When to keep humans in the loop (29:33) What makes automating biology different (31:19) Industry trends for the next decade (34:55) Most rewarding part of building Monomer (37:32) Advice for listeners Links: Monomer Bio: https://www.monomerbio.com/

Guest: Jason Kelly, CEO and co-founder of Gingko BioworksAlmost everyone in the second generation of biotechnology entrepreneurs, says Gingko Bioworks CEO Jason Kelly, works in that field because of one thing: Jurassic Park. The Michael Crichton novel-turned-Steven Spielberg movie captured both the wonder and beauty of bioengineering, and the challenges of bending DNA to your own ends. “You didn't invent biology,” Jason says. “You need to have humility in the face of it ... because life will find a way. It will do things you don't expect. It's not a computer.” In this episode, Jason and Joubin discuss the Wall Street rollercoaster, designer cells, the history of biotech, Herbert Boyer and Genentech, ChatGPT, extinct flowers, Sam Altman and YCombinator, first principles thinking, compounding risk, Patrick Collison, super-voting shares, capital intensive businesses, Pets.com, and why biology is like “freakishly powerful alien technology.”In this episode, we cover:Being private vs. being public (00:58)How bioengineering works (04:27)Jurassic Park (08:51)Biotech breakthroughs (12:15)Why this field is not well-known yet (16:57)“The ChatGPT moment for biotech” (22:05)Meaningful stuff takes forever (26:23)Gingko's first five years (29:02)Why the company went public (36:20)Short sellers, Warren Buffett, and Elon Musk (42:08)Applying AI to DNA engineering (47:57)The long-term future (55:57)Who Gingko is hiring (58:39)Links:Connect with JasonTwitterLinkedInConnect with JoubinTwitterLinkedInEmail: grit@kleinerperkins.com Learn more about Kleiner PerkinsThis episode was edited by Eric Johnson from LightningPod.fm

with

Radio Boston explores Boston-based Gingko Bioworks' new initiative to track COVID using airplane wastewater treatments.

The topics, stocks and shares mentions / discussed include: Rolls Royce the defence winner? The Apple phenomenon Do you know your $DNA? Gingko Bioworks Holdings Games Workshop / GAW Accenture / ACN Artificial Intelligence / Ai Kier / KIE Construction / Infrastructure S4 Capital / SFOR Advertising spend Averaging down risks Portmeirion / PMP FTSE 100 AIM All-Share Rentokil /RTO Rollins / ROL RTC Group / RTC Gresham House takeover premium / GHE MNA, takeover, consolidation opportunities Investment Trusts / Investment companies discounts Interest rates / Inflation Investing Psychology / Home Bias Book recommendation: The Investment Trusts Handbook 2023 by Jonathan Davis Harriman House books Powder Monkey Brewing Co 5% discount code : TWINPETES Menphys Charity Appeal please make a donation on the TwinPetes Investing Challenge 2023 Just Giving Page Kindness / Charity Trading & more The Twin Petes Challenge 2023 / Charity fundraise for the MENPHYS Charity. Have you enjoyed one or more of these podcasts. Yes . Then please make a donation , every pound will help. JUST GIVING TWIN PETES FUNDRAISING FOR THE MENPHYS CHARITY https://www.justgiving.com/fundraising/twinpeteschallenge23 Thank you. The Twin Petes Investing podcasts will be linked to and written about on the Conkers3 website and also on the WheelieDealer website . Thank you for reading this article and listening to this podcast, we hope you enjoyed it. Please share this article with others that you know will find it of interest. PLEASE SUBSCRIBE TO THE TWIN PETES INVESTING PLATFORM THAT YOU ARE LISTENING TO THIS PODCAST ON. THANK YOU.

In this video we examine the suspect business of Gingko Bioworks.

In today's podcast episode, I talk with Renee Wegrzyn,  appointed by President Biden as the first director of a federal agency created last year called the Advanced Research Projects Agency for Health, or ARPA-H. It's inspired by DARPA, the agency that develops innovations for the Defense department and has been credited with hatching world changing technologies such as ARPANET, which became the internet.Time will tell if ARPA-H will lead to similar achievements in the realm of health. That's what President Biden and Congress expect in return for funding ARPA-H at 2.5 billion dollars over three years. How will the agency figure out which projects to take on, especially with so many patient advocates for different diseases demanding moonshot funding for rapid progress. I talked with Dr. Wegrzyn about the opportunities and challenges, what lessons ARPA-H is borrowing from Operation Warp Speed, how she decided on the first ARPA-H project which was just announced recently, why a separate agency was needed instead of trying to reform HHS and the National Institutes of Health to be better at innovation, and how ARPA-H will make progress on disease prevention in addition to treatments for cancer, Alzheimer's and diabetes, among many other health priorities.Dr. Wegrzyn's resume is filled with experience for her important role. She was a program manager at DARPA where she focused on applying gene editing and synthetic biology to the goal of improving biosecurity. For her work there, she was given the Superior Public Service Medal and, just in case that wasn't enough ARPA experience, she also worked at another ARPA that leads advanced projects in intelligence, called I-ARPA. Before that, she was in charge of technical teams in the private sector working on gene therapies and disease diagnostics, among other areas. She has been a vice president of business development at Gingko Bioworks and headed innovation at Concentric by Gingko. Her training and education includes a PhD and undergraduate degree in applied biology from the Georgia Institute of Technology and she did her postdoc as an Alexander von Humboldt Fellow in Heidelberg, Germany.As Dr. Wegrzyn told me, she's “in the hot seat” - the pressure is on for ARPA-H especially after the need and potential for health innovation was spot lit by the pandemic and the unprecedented speed of vaccine development. We'll soon find out if ARPA-H can produce something in health that's equivalent to DARPA's creation of the internet.Show links:ARPA-H - https://arpa-h.gov/Dr. Wegrzyn profile - https://arpa-h.gov/people/renee-wegrzyn/Dr. Wegrzyn Twitter - https://twitter.com/rwegrzyn?lang=enPresident Biden Announces Dr. Wegrzyn's appointment - https://www.whitehouse.gov/briefing-room/statements-releases/2022/09/12/president-biden-announces-intent-to-appoint-dr-renee-wegrzyn-as-inaugural-director-of-advanced-research-projects-agency-for-health-arpa-h/Leaps.org coverage of ARPA-H - https://leaps.org/arpa/ARPA-H program for joints to heal themselves - https://arpa-h.gov/news/nitro/ - ARPA-H virtual talent search - https://arpa-h.gov/news/aco-talent-search/Leaps.org is a not-for-profit initiative that publishes award-winning journalism, popularizes scientific progress on social media, and hosts events about bioethics and the future of humanity. Visit the platform at www.leaps.org. Podcast host Matt Fuchs is editor-in-chief of Leaps.org.

Tony Strobbe is EV supply chain Projects Director. Every Monday, he compiles a dedicated content piece he shares on LinkedIn that covers one aspect of that said supply chain, so if you like what he shares today, make sure to follow him! I hope you haven't missed last week's conversation with Ben Sparrow from Saltworks! If you have, shame on you, but let me bring you up to speed: we're diving into the lithium value chain to discuss, evaluate and uncover the opportunities for water technologies and professionals in this rapidly growing application that taps into several layers of the water industry. Now when you visit a foreign country, it's often a smart move to start by getting the basics of language and culture. So that's the mission I tasked Tony with today: let us break down the fundamentals of lithium processes. Why, where, and how do we refine lithium. What do we need to know on the technical side of the equation, but also on the geopolitical aspect of things. Where does the lithium value chain sit in the greater scheme of the EV supply chain? Those are just some of the questions we'll get to answer today. And that will give us valuable keys to leverage the next nuggets in this series, such as the company that shall build the first ever commercial scale Direct Lithium Extraction project, or the dedicated team within the World's largest water company that's conceived some of the most emblematic lithium refining projects.  Before kicking off, let me just share with you that I'm back from the Global Water Summit in Berlin and then the BlueTech Forum in Edinburg; it was a great experience to get to meet many of you and to discuss water, wastewater, water entrepreneurship, and much more. I'm so grateful for the many heartwarming feedbacks you gave me on the podcast, it means the World to me, and beyond just an ego-boost, it's critically important for me as I strive to produce you the most useful content every week. If it's the case, I'm glad it is, and you can help me out by sharing the pod with your friends, colleagues, boss, or team. Yet if you feel there's something I shall be doing differently or better, hey, feedback doesn't have to be positive: come share me your thoughts on LinkedIn or by mail: antoine@dww.show. I also came back from both Berlin and Edinburg with great pieces of content, I spoke with the GWI team and the BlueTech team, I also cut some quite insightful interviews with Xylem, Veolia, Aquatech, Kemira, Evoqua, Gingko Bioworks, and more, I can't wait to share you all of this, once I've digested and edited it, but enough for that sidetrack and all that teasing, I'll leave the floor to Tony, and I'll meet you on the other side.  ➡️ Check out the entire article on how to sell smaller-sized Water Companies, including an infographic and a full transcript on the (don't) Waste Water website!

Today I'm interviewing HonMun Yip, currently asset manager for KICL Group which manages investments but he does a lot of stuff. Mainly, he's invested in a ton of alternative protein companies as an early-stage investor. His list can be found on LinkedIn but some of his portfolios includes but is definitively not limited to: Impossible Foods, Eat JUST, Motif Foodworks, Gingko Bioworks, and Youkuai Meats. HonMun has been through it all in his career seeing the rise and fall of the dot com era and the eventual adoption of the smartphone era and now he's in the action of the food tech era. In this interview, you'll gain deep insight on a bird's eye vision. HonMun compares the current food tech landscape like the smartphone industry. It took 30 years to fruition so as an investor, you have to recognize trends and stay for the long term I caught HonMun right after his trip to the United States, and he tells me just how exciting it is to see the technology progressing and the energy that exudes from meeting with founders face to face. What's important to mention in this interview is that HonMun sees one thing that resonates in this sector. Purpose. Compared to the digital age, food is so connected and so personal, the potential benefits to the world are blatantly obvious, that the investor community notices the intense passion of these entrepreneurs. One quote I always love from mark Twain is that history doesn't repeat itself, it rhymes and I think it bares repeating this over and over again. I think we need this focus whenever it comes to exciting new technologies. Enjoy this Interview with HonMun Yip. We do this in some corporate office in Singapore. Shownotes: http://myfoodjobrocks.com/261HonMun

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Biden should be applauded for appointing Renee Wegrzyn for ARPA-H, published by ChristianKl on September 18, 2022 on LessWrong. When Biden first announced ARPA-H (Advanced Research Projects Agency for Health) I was skeptical. At the time the proposal was to make ARPA-H a normal agency within the NIH. When critics argued that the NIH bureaucracy would likely reduce the amount of innovation that ARPA-H could produce the administration listened and US health secretary Xavier Becerra decided to make ARPA-H an independent entity within the NIH. Appointing Renee Wegrzyn as the head of ARPA-H is an excellent choice. Having previously worked at DARPA and IARPA and not in the NIH makes her a good person to copy the structure of how DARPA and IARPA get things done. Being 45, she is twenty years younger than the average director of an institute at the NIH who is 65. When science sometimes evolves from gravestone to gravestone, it's great to see a director for the ARPA-H who's in her forties. Especially, in contrast to the newly appointed NIH director Lawrence A. Tabak who is a 71-year-old (a fact that his NIH biography omits) having a 45-year-old lead ARPA-H is a welcome surprise. While at DARPA, Wegrzyn worked on biosecurity and even gave a talk about the importance of biosecurity to the Long Now Foundation. It's valuable to have people who care about biosecurity at the top of organizations that direct a lot of research dollars. A lot of the research focuses either on directly curing diseases or on basic research but the research that focuses on producing tools for better research is historically underfunded. Wegrzyn experience as vice president of business development at Gingko Bioworks which is a unicorn biotech company that historically doesn't focus on curing diseases directly but providing tools to help other companies, gives me hope that ARPA-H will be able to fund research into producing better tools to deal with biological problems. During COVID-19 they worked on producing COVID tests which was likely a lesson in the flaws of government bureaucracy holding back innovation. In an interview she described her own research as being guided by the question of ‘what do we know about protein folding that can help us develop a totally new type of diagnostic?' I'm happy to see that and think it will lead to better research paths than having someone who focuses more on creating FDA approved drugs in charge of allocating research funding. She coedited Alzheimer's Disease Targets for New Clinical Diagnostic and Therapeutic Strategies in 2012. It seems to me that one of the more important issues in Alzheimers research funding is the overinvestment in the amyloid cascade hypothesis. The book gets that issue right when it argues “Until recently, the amyloid cascade hypothesis had been the predominant working hypothesis for AD pathogenesis. However, this hypothesis has been supplanted by what some have called the oligomer cascade hypothesis, which posits that Aβ oligomers, rather than fibrils, are the proximate neurotoxic agents in AD” I think she showed excellent judgment by writing a book that argued for directing our Alzheimer research dollar to other paths than the amyloid cascade hypothesis (that part isn't written by her directly). In the essay that she wrote herself, she argues “Drug discovery and development for the treatment of Alzheimer's disease would greatly benefit from biomarkers that are predictive of clinical outcomes to inform the selection of effective drug candidates, monitor dose safety and efficacy on treated cohorts, and identify or confirm the mechanisms of drug action in hopes of developing treatments that go beyond symptomatic relief and are disease modifying. The ability to monitor disease progression longitudinally during patient treatment will also be key to...

Link to original articleWelcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Biden should be applauded for appointing Renee Wegrzyn for ARPA-H, published by ChristianKl on September 18, 2022 on LessWrong. When Biden first announced ARPA-H (Advanced Research Projects Agency for Health) I was skeptical. At the time the proposal was to make ARPA-H a normal agency within the NIH. When critics argued that the NIH bureaucracy would likely reduce the amount of innovation that ARPA-H could produce the administration listened and US health secretary Xavier Becerra decided to make ARPA-H an independent entity within the NIH. Appointing Renee Wegrzyn as the head of ARPA-H is an excellent choice. Having previously worked at DARPA and IARPA and not in the NIH makes her a good person to copy the structure of how DARPA and IARPA get things done. Being 45, she is twenty years younger than the average director of an institute at the NIH who is 65. When science sometimes evolves from gravestone to gravestone, it's great to see a director for the ARPA-H who's in her forties. Especially, in contrast to the newly appointed NIH director Lawrence A. Tabak who is a 71-year-old (a fact that his NIH biography omits) having a 45-year-old lead ARPA-H is a welcome surprise. While at DARPA, Wegrzyn worked on biosecurity and even gave a talk about the importance of biosecurity to the Long Now Foundation. It's valuable to have people who care about biosecurity at the top of organizations that direct a lot of research dollars. A lot of the research focuses either on directly curing diseases or on basic research but the research that focuses on producing tools for better research is historically underfunded. Wegrzyn experience as vice president of business development at Gingko Bioworks which is a unicorn biotech company that historically doesn't focus on curing diseases directly but providing tools to help other companies, gives me hope that ARPA-H will be able to fund research into producing better tools to deal with biological problems. During COVID-19 they worked on producing COVID tests which was likely a lesson in the flaws of government bureaucracy holding back innovation. In an interview she described her own research as being guided by the question of ‘what do we know about protein folding that can help us develop a totally new type of diagnostic?' I'm happy to see that and think it will lead to better research paths than having someone who focuses more on creating FDA approved drugs in charge of allocating research funding. She coedited Alzheimer's Disease Targets for New Clinical Diagnostic and Therapeutic Strategies in 2012. It seems to me that one of the more important issues in Alzheimers research funding is the overinvestment in the amyloid cascade hypothesis. The book gets that issue right when it argues “Until recently, the amyloid cascade hypothesis had been the predominant working hypothesis for AD pathogenesis. However, this hypothesis has been supplanted by what some have called the oligomer cascade hypothesis, which posits that Aβ oligomers, rather than fibrils, are the proximate neurotoxic agents in AD” I think she showed excellent judgment by writing a book that argued for directing our Alzheimer research dollar to other paths than the amyloid cascade hypothesis (that part isn't written by her directly). In the essay that she wrote herself, she argues “Drug discovery and development for the treatment of Alzheimer's disease would greatly benefit from biomarkers that are predictive of clinical outcomes to inform the selection of effective drug candidates, monitor dose safety and efficacy on treated cohorts, and identify or confirm the mechanisms of drug action in hopes of developing treatments that go beyond symptomatic relief and are disease modifying. The ability to monitor disease progression longitudinally during patient treatment will also be key to...

"The future is synthetic."How do you feel about synthetics? Are you thinking about a wildly sticky, static electric, polyester shirt right now? Many of us have negative connotations of synthetics as something unnatural, artificial and based on ancient fossil fueled techniques. The history of science up until now has placed nature by definition as separate and below humans, thereby creating a division between nature and technology. Christina Agapakis from Gingko Bioworks introduces in her talk the “meatverse”, her vivid vision for society, where we (re)unite technology and nature. She asks big questions like how might we create a new kind of culture around biological development with nature? How might we design biological tools regenerative for all beings without the use of fossil fuels? How might biological programmers log into the ‘wood wide web' to help co-create new forests?She closes her talk with a call to celebrate nature and technology and to reflect how we might use nature without filling the world with garbage.

Christina Agapakis is a biologist, writer, and artist known for her experiments exploring the future of biotechnology. She is creative director at Ginkgo Bioworks, a synthetic biology company that specializes in prototyping, designing, and licensing bioengineered microbes to a variety of industries.

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Nando Sommerfeldt und Holger Zschäpitz über die ewige K+S-Rallye, die gigantische Öko-Prognose des Larry Fink und einen Oha-Effekt bei JP Morgan. Außerdem geht es um Adidas, Paypal, Zscaler,Crowdstrike, Datadog, Gingko Bioworks, TuSimple, Roblox, Unity Software, ARK Innovation (WKN: A14Y8H), Auto1 Group, Blackrock, iShares Global Clean Energy (WKN: A0MW0M), Warner Bros. Discovery, Tui, Hometogo, Carnival, Norwegian Cruise Line, Royal Caribbean, iShares STOXX Europe 600 Travel & Leisure ETF (A0H08S) und HANetf Airlines, Hotels, Cruise Lines (A3CPGE). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++Werbung+++ Hier geht's zur App: Scalable Capital ist der Broker mit Flatrate. Unbegrenzt Aktien traden und alle ETFs kostenlos besparen – für nur 2,99 € im Monat, ohne weitere Kosten. Und jetzt ab aufs Parkett, die Scalable App downloaden und loslegen. Hier geht's zur App: https://bit.ly/3abrHQm Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

@AviNMash and @AnthonyOhayon discuss if it is time to feel bullish? What happened with Tesla Split? Are AMC and GME about to go round 2? Gingko Bioworks and Sema4 might not suck anymore? $SHOP $GME $AMC $TSLA $DNA $SMFR $BTC $ETH Huge shout out to our sponsors at StockTwits our favorite place to get a pulse of what people are saying about our favorite ticker symbols in both Stocks and Crypto www.StockTwits.com

หมู่คณะแขกรับเชิญในตอนนี้ รวมตัวกันมาจากเพจนำเสนอคอนเท็นต์วิทยาศาสตร์หน้าใหม่ The Principia (เว็บไซต์ https://theprincipia.co/) ฟังแล้วชอบ อย่าลืมไปติดตามและสนับสนุนกันนะครับ TIME STAMPS 0:00 เกริ่นนำ ทักทาย แนะนำแก๊งค์ The Principia (เต้,กน,ภูริ,นิก,หญิง,เฟิส) 21:34 เข้าไฮไลท์ข่าวใหญ่ปี 2021 - โควิดกลายพันธุ์ 40:05 คุณนิกเล่าข่าวการสำรวจอวกาศช่วงต้นปี หลายประเทศส่งยานไปดาวอังคารพร้อมๆ กัน 54:52 เต้เล่าข่าวบรรพชีวิน เบบี้หยิงเหลียง (Baby Yingliang) กับซากเซลล์และ DNA อายุ 125 ล้านปี + คุยเรื่องโคลนแมมอธ + แมลงยักษ์ๆ สมัยก่อน 1:12:01 บริษัทไบโอเทคมาแรง Gingko Bioworks รับออกแบบสิ่งมีชีวิต 1:18:20 คุณนิกเล่าข่าวอวกาศช่วงกลางปี 2021 โครงการ DART + การไปอวกาศของคนธรรมดาที่ไม่ใช่นักบินอวกาศ 1:50:00 เฟิสเล่าข่าวพฤติกรรมหนอนผีเสื้อกับมด 2:02:35 เต้สรุป Metaverse 2:24:40 พูดคุยเพิ่มเรื่องประวัติแต่ละคน 2:15:48 เฟิสเล่าข่าวเจอด้วงพันธุ์ใหม่ที่อยู่ในรังกับปลวก 2:37:15 คุณนิกพูดถึงกล้อง James Webb ความน่าทึ่งของการที่มนุษย์สามารถมองย้อนกลับไปในอดีต และในความยิ่งใหญ่ของเอกภพ คลิปไลฟ์สด https://www.youtube.com/watch?v=aiiaD4Z1G98 ข่าวใหญ่สุดแห่งปีที่ผ่านมาคงหนีไม่พ้นการเกิดวิวัฒนาการ variant ต่างๆ ของโควิดที่ติดง่ายกว่าเดิม ทั้ง delta และ omicron ข่าวการสำรวจอวกาศช่วงต้นปี สหรัฐอาหรับเอมิเรตส์ จีน และอเมริกา ส่งยานไปดาวอังคารพร้อมๆ กัน ข่าวงการบรรพชีวิน เบบี้หยิงเหลียง (Baby Yingliang) ฟอสซิลตัวอ่อนไดโนเสาร์ในไข่ที่สมบูรณ์ที่สุด -1 ข่าวเจอฟอสซิลเซลล์และซาก DNA ไดโนเสาร์อายุ 125 ล้านปี -1,2,3 Gingko Bioworks บริษัทไบโอเทคที่ระดมทุนได้สูงเป็นประวัติกาลในปีที่ผ่านมา https://www.facebook.com/biologybeyondnature/photos/a.680275942134989/825065140989401/?__cft__[0]=AZVgH0T3u6pqJFHbHQpgv0soMVtEk1-s_4PpX77iuJBl6vaDEX2lyNuacJYWk_0yqBaan7qZX1ZSxHpC2cDhRlh56FXgvm2dt_pOLLnu9wTVeDcLP916jQm0WKDeundqh66_G7x4BEVyJJ6795HgFML3&__tn__=%2CO*F ข่าวอวกาศช่วงกลางปี 2021 โครงการ DART (Double Asteroid Redirection Test ) ทดลองส่งยานไปพุ่งชนดาวเคราห์น้อย ดูว่าจะเบี่ยงทิศทางมันได้มั้ย 2021 ปีแห่งการไปอวกาศของคนที่ไม่ใช่นักบินอวกาศ คุณ Wally Funk อายุ 82 กับ William Shatner อายุ 90 ไปกับ Blue Origin โครงการ Inspiration4 ของ SpaceX The Inspiration4 crew of Chris Sembroski, Sian Proctor, Jared Isaacman and Hayley Arceneaux poses in this picture obtained by Reuters on September 15, 2021. INSPIRATION 4/Handout via REUTERS การค้นพบแมลงน่าสนใจ หนอนผีเสื้อใช้ยาเสพติดล่อมดมาเป็นบริวาร -1,2 หนอนผีเสื้อใช้กลิ่นหลอกมดให้เอามันไปเลี้ยงในรัง-1 เจอด้วงชนิดใหม่ (Termitotrox icarus) ที่อาศัยอยู่กับปลวกในรัง -1 ปล่อยกล้อง James Webb สำเร็จ รอติดตามดูรูปที่จะถ่ายได้ โครงการ cosmic telescope - 1 โครงการ Breakthrough Starshot

In der heutigen Folge „Alles auf Aktien“ berichten die Finanzjournalisten Anja Ettel und Holger Zschäpitz über Holland in Not, Oprah Winfreys Irrtum und die geheimen Wetten der Profis. Außerdem geht es um Home24, Royal Dutch Shell, Unilever, Gamestop, Oatly, Deutsche Telekom, Goldman Sachs Hedge Industry VIP ETF (WKN: A2DWAV), Gingko Bioworks, Lucid Motors, AirBnB, Adobe, Alibaba, Nio, JD, Sea Lmt, Doordash, Cloudflare, Snowflake, Square, Salesforce, Intuitive Surgical, Ui Path, IHS Markit, Palantir, Microsoft, Docusign Adobe, Chipotle Mexican Grill,Visa, Mastercard, Robinhood, Warby Parker, Gingko Bioworks, Lucid Motors, AirBnB, Bank of America, Citi, JPM, Morgan Stanley, Wells Fargo, Ebay, Apple, Meta Platforms, Walt Disney, Amazon Roku, TuSimple, Goldman Sachs Hedge Industry VIP ETF (WKN: A2DWAV), Ark Innovation (WKN: A14Y8H), Tesla, Amplify Transformational Data Sharing ETF (WKN: A2JB5E), Silvergate, Galaxy Digital Holdings, Coinbase, Twitter, Visa, Paypal, IBM, Riot Blockchain, Marathon Digital Holdings, Wisdomtree. "Alles auf Aktien" ist der tägliche Börsen-Shot aus der WELT-Wirtschaftsredaktion. Die Wirtschafts- und Finanzjournalisten Holger Zschäpitz, Anja Ettel, Philipp Vetter, Daniel Eckert und Nando Sommerfeld diskutieren im Wechsel über die wichtigsten News an den Märkten und das Finanzthema des Tages. Außerdem gibt es jeden Tag eine Inspiration, die das Leben leichter machen soll. In nur zehn Minuten geht es um alles, was man aktuell über Aktien, ETFs, Fonds und erfolgreiche Geldanlage wissen sollte. Für erfahrene Anleger und Neueinsteiger. Montag bis Freitag, ab 5 Uhr morgens. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem neu bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++Werbung+++ Hier geht's zur App: Scalable Capital ist der Broker mit Flatrate. Unbegrenzt Aktien traden und alle ETFs kostenlos besparen – für nur 2,99 € im Monat, ohne weitere Kosten. Und jetzt ab aufs Parkett, die Scalable App downloaden und loslegen. Hier geht's zur App: https://bit.ly/3abrHQm

We chat with Anna Marie Wagner, the SVP of corporate development at Gingko Bioworks, a synthetic biology company that recently came public and is part of Invest Vegan's flagship strategy. We chat about how Gingko evolved its funding sources over time, the firm's decision to pursue a horizontal/service provider business model, and how she'll judge the success of her company and the broader synthetic biology industry going forward.

Youngme, Felix, and Mihir discuss the red hot IPO market, highlighting a few of the companies reflecting a “sign of the times” including: Rivian Automotive, Duolingo, and life science companies like Gingko Bioworks and Moderna. They also answer a few letters from listeners, including questions about the soaring valuations of private company unicorns, the latest Facebook scandal, and more. Recent picks, and recommended reading/websites: ·       Private Company Unicorns (Crunchbase) ·       Run for Office (Snapchat Mini) ·       Career and Family (Claudia Goldin) ·       Journey Across a Century of Women (Claudia Goldin) ·       How to Make Ppopgi (Honeycomb Candy, as featured in Squid Game)  We invite you to email your comments and ideas for future episodes to:  afterhours@hbs.edu.  You can also follow Youngme and Mihir on Twitter at: @YoungmeMoon and @DesaiMihirA.

Jasmina is a beauty industry pioneer who is passionate about translating innovation into meaningful brands that connect us with the miracle of biology. Her previous company, Mother Dirt, included a line of products focused on the skin microbiome. The hero product restores Ammonia-Oxidizing Bacteria (AOB), which current hygiene practices have stripped from the skin. Now, Jasmina is working with the powerful Ginkgo Foundry to see what we can learn from nature and  harness through microbes for use in the personal care industry.  We talk to Jasmina about the incredible potential of this work and how it reminds us that natural, biological intelligence is the oldest and often most reliable intelligence of all.Learn more:Website - https://www.ginkgobioworks.com/Also mentioned:C16 BioSciences (synthetic palm oil) - https://www.c16bio.com/

This week, Monica and Jennifer sit down with Jasmina Aganovic to talk about all things beauty and biotechnology. After earning a degree in Chemical and Biological Engineering from MIT, Jasmina worked with well-known beauty brands like Fresh and Living Proof before founding her own line, Mother Dirt, a brand that uses the naturally occurring bacteria found on human skin to treat and cleanse without stripping. Currently, Jasmina is the entrepreneur in residence at Gingko Bioworks, a biotechnology company working to bring nature to the forefront in innovation. We cover a lot of ground in this episode including Gingko's partnership with Moderna, the weaknesses of the ‘clean' beauty industry, and why biology is the ultimate technology. Show NotesGingko Bioworks: The Organism CompanyGrow by GingkoNo Soap, No Shampoo, Bacteria-Rich Hygiene Experiment, by Julia Scott (The New York Times)Laboratory of Longings by Ani LiuDue to the increasing spread of Covid-19, we are taking the 2021 Biophilic Leadership Summit virtual. From the safety and comfort of your home or office, join thought-leaders for workshops, presentations, and engaging Q/As on the ‘biophilia effect' on health, climate change, policy, and future developments with a focus on Biophilia at Scale: Land and Water presentations focusing on land use and infrastructure. Join the Biophilic Movement on October 11th and October 12th, 2021, hosted by The B

Today, we will be diving into Moderna. Founded in 2010, Moderna and its innovative RNA platform made headlines after developing one of the first COVID vaccines. We treated this Breakdown slightly different than our other episodes. I'm joined today by two guests. First, I am joined by Jason Kelly, CEO of Gingko Bioworks. He gives us a primer on the biotech industry, genetic modification, and how Moderna's platform represents a new breakthrough in the industry. Then, I talk to Matthew Harrison, a biotech analyst at Morgan Stanley. We will cover what differentiates Moderna's business model, how Moderna's science could lead to faster and higher efficacy drug development, and key takeaways for investors and operators. I hope you enjoy this Breakdown of Moderna.   For the full show notes, transcript, and links to the best content to learn more, check out the episode page here. -----   This episode is brought to you by Canalyst. Canalyst is the leading destination for public company data and analysis. If you enjoy our exploration of what makes a company tick on Business Breakdowns, Canalyst should be the foundation for your quantitative analysis. For more information and access to the Canalyst model on the business we break down in this episode, go to canalyst.com/breakdowns.   -----   Business Breakdowns is a property of Colossus, Inc. For more episodes of Business Breakdowns, visit joincolossus.com/episodes.   Stay up to date on all our podcasts by signing up to Colossus Weekly, our quick dive every Sunday highlighting the top business and investing concepts from our podcasts and the best of what we read that week. Sign up here.   Follow us on Twitter: @JoinColossus | @patrick_oshag | @jspujji | @zbfuss   Show Notes - Part 1: Jason Kelly [00:02:31] - [First question] - What is a biotech company? [00:03:50] - Defining Moderna as a company in the biotech space [00:05:15] - Bridging the gap between biotech and genentech [00:06:02] - Overview of the history of learning to program cells [00:07:46] - Big milestones from the discovery to the human genome project [00:10:03] - Technical process and tool of how one modifies and copies genes [00:11:45] - The scale and tools of modern DNA design [00:11:41] - Defining printing DNA sequences [00:14:05] - What the Moderna vaccine is and how it works [00:17:24] - The first engineered drug of its kind  [00:18:24] - Other areas where synthetic biology appears in everyday life [00:22:19] - How many sectors this type of technology will disrupt [00:23:32] - The history of Moderna and how they came to be [00:24:41] - What problem Moderna tries to solve and how they approach it [00:27:11] - Unique deal components in therapeutics and the FDA [00:29:06] - Key factors that will make Moderna a dominant player in the near future  [00:30:01] - How Genentech became as big as they did  [00:30:53] - Competitive and compounded advantages for biotech companies [00:32:09] - Lessons for investors and entrepreneurs in studying Moderna's story   Show Notes - Part 2: Matthew Harrison  [00:34:10] - What is Moderna and how it got started [00:36:10] - Typical route taken for a drug maker and how Moderna is different [00:37:16] - What separates Moderna from others in the biotech space today [00:39:12] - The role software and technology has played a role in Moderna's success [00:41:42] - Cementing their position through breakthroughs and capitalizing on them  [00:42:58] - How Moderna generates their revenue  [00:44:45] - Overview of cost of sales, expense buckets and gross margin [00:46:20] - Factors involved in how one valuates a biotech company [00:47:15] - How many drugs are in Moderna's pipeline compared to others [00:47:45] - Drugs being developed that aren't so currently controversial  [00:51:26] - Risks of drug development and their market potential [00:54:01] - Internal operations of drug development and what separates Moderna [00:55:30] - Advantages of having the ability to customize drug delivery [00:57:17] - Comparing Moderna's mRNA to others on the market  [00:59:44] - High level breakdown of pharmaceutical R&D [01:01:33] - Other P&L and financial components that arise given the nature of biotech  [01:03:09] - Contrast between the Moderna and Pfizer vaccine [01:04:18] - What Moderna will have to get right in order to become the next Pfizer  [01:05:38] - What Moderna would have to get wrong to limit their growth [01:07:24] - Company culture and the importance of management [01:08:06] - Lessons for builders and entrepreneurs in studying Moderna's story

Daniel sat down with Dr. Dylan George, a biosecurity and data expert from Gingko Bioworks. Dylan's career spans academia and a number of roles in the federal government — advising the Obama administration on Ebola and, more recently, advising the Biden-Harris transition team on COVID-19. If data is the new oil, it's also the new way of protecting our kids, our families, and our communities.

Carl Quintanilla, Jim Cramer and David Faber led off the show by discussing the extension of the tech sell-off dragging down the markets overall -- with Tesla, semiconductors and FAANG names among those under pressure. Cathie Wood's ARK Innovation ETF extending losses of its own, down more than 14-percent for the month. The anchors explored whether now's the time to buy some of the ETF's beaten-down components such as Zoom, Roku and Twilio. They also reacted to what billionaire investor Stanley Druckenmiller told CNBC about Fed policymakers -- he says they are failing to adjust to improved economic conditions by clinging to an emergency policy. Also in focus: The EPA's response to the Colonial Pipeline ransomware attack and what it could mean for gas prices, Biotech firm Gingko Bioworks agreeing to go public in a $15-billion SPAC Deal, What the CEO of Simon Property Group is saying about earnings and what he's seeing from shoppers at the malls, and L Brands' decision to spin off Victoria's Secret and Bath & Body Works into two public companies.

This week Dr. Jason Kelly, co-founder and CEO of Gingko Bioworks, returns to join us again for another Uniquely Rockefeller Special Client Event. Listen in as Greg Fleming and Dr. Kelly discuss the latest on COVID-19 testing and take questions from colleagues and clients. Introduction by Thomas Martella, AVP, Platform Development Rockefeller Capital Management. Originally broadcast live September 22, 2020.

In this episode we are joined by Dr. Christina Agapakis. Christina is a synthetic biologist, artist, and writer. She is the Creative Director of Gingko Bioworks, a boston based biotech company, and the Executive Editor of Grow Magazine, a magazine focused on  the current endeavors, neglected histories, and collective futures in synthetic biology.    As creative director, Christina engages with people, policies, and potential futures involved in synthetic biology, working for more open, equitable, and renewable technologies.   In the lab, Christina has worked on enzymes involved in the production of biofuels, ecological design principles for synthetic biology, and the evolution of microbial communities in the soil. As an artist, she's mapped the microbial diversity of California, isolated halophilic bacteria from the Salton Sea, and made cheese from bacteria living on human skin.   https://www.agapakis.com/   https://www.growbyginkgo.com/   https://www.ted.com/talks/christina_agapakis_what_happens_when_biology_becomes_technology

The ability to produce COVID vaccines in record time only scratches the surface of what synthetic biology can do. Gingko Bioworks out of Boston is now 3-D printing millions of letters of DNA code and then using CRISPR to insert them into living cells, transforming what’s scientifically possible.

Where the coronavirus came from and why these diseases aren't a one-off. Manuela Saragosa speaks to Dr Juan Lubroth, former chief veterinary officer at the UN's Food and Agricultural Association in Rome, about the risks around so-called 'wet' markets prevalent in East Asia and South East Asia where live animals are sold. Professor Tim Benton, research director of the emerging risks team at the think tank Chatham House tells us why animals are often the source of pathogens that go on to affect humans. Patrick Boyle, a bioengineer with US biotech company Gingko Bioworks, describes the work to develop vaccines. Catherine Rhodes from the Biosecurity Research Initiative at Cambridge University tells us why she's not surprised governments are underprepared for the pandemic. Producer: Laurence Knight (Photo: A wet market in Taipei, Taiwan. Credit: Getty Images)

Under Satya Nadella, Microsoft has reclaimed its crown as the world’s most valuable listed company. What can other firms learn from its reboot? Also, Reshma Shetty, cofounder of Gingko Bioworks, explains the potential of synthetic biology to harness – and transform – the power of nature. And, British ethicists put police use of artificial intelligence on trial. Alok Jha hosts See acast.com/privacy for privacy and opt-out information.

Under Satya Nadella, Microsoft has reclaimed its crown as the world’s most valuable listed company. What can other firms learn from its reboot? Also, Reshma Shetty, cofounder of Gingko Bioworks, explains the potential of synthetic biology to harness – and transform – the power of nature. And, British ethicists put police use of artificial intelligence on trial. Alok Jha hosts See acast.com/privacy for privacy and opt-out information.

In this episode of Startup School Radio, host Aaron Harris interviews Ambition co-founder Brian Trautschold and Gingko Bioworks co-founder Dr. Jason Kelly

Bryan Johnson is an entrepreneur and investor. He is the founder of OS Fund and Braintree, the latter of which was bought by eBay in 2013 for $800 million in cash. Bryan launched OS Fund in 2014 with $100 million of his personal capital to support inventors and scientists who aim to benefit humanity by rewriting the operating systems of life. He cultivates real-world mad scientists. Our conversation includes his rags to riches story (and strategies), his philosophical hardwiring, negotiating/sales tactics, and even parenting. We cover a ton of ground with a fascinating and deep mind. Bryan's investments include endeavors to cure age-related diseases and radically extend healthy human life to 100+ (Human Longevity), make biology a predictable programming language (Gingko Bioworks & Synthetic Genomics), replicate the human visual cortex using artificial intelligence (Vicarious), mine an asteroid (Planetary Resources), reinvent transportation using autonomous vehicles (Mattternet), and reimagine food using biology (Hampton Creek), among others. Enjoy! Please check out the sponsors for this episode, which I’ve used myself: Athletic Greens —My all-in-one nutritional insurance policy. 99Designs — Your one-stop shop for all things graphic design related. I used them for the book cover mockups for The 4-Hour Body, which later hit #1 New York Times. Show notes (links, resources, books, etc.) from this episode can be found on my blog here: http://fourhourworkweek.com/podcast.***If you enjoy the podcast, would you please consider leaving a short review on Apple Podcasts/iTunes? It takes less than 60 seconds, and it really makes a difference in helping to convince hard-to-get guests. I also love reading the reviews!For show notes and past guests, please visit tim.blog/podcast.Sign up for Tim’s email newsletter (“5-Bullet Friday”) at tim.blog/friday.For transcripts of episodes, go to tim.blog/transcripts.Interested in sponsoring the podcast? Visit tim.blog/sponsor and fill out the form.Discover Tim’s books: tim.blog/books.Follow Tim:Twitter: twitter.com/tferriss Instagram: instagram.com/timferrissFacebook: facebook.com/timferriss YouTube: youtube.com/timferriss